Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RO7616789 |
| Trade Name | |
| Synonyms | RO 7616789|RO-7616789|RG6524|RG-6524|RG 6524|ALPS-12 |
| Drug Descriptions |
RO7616789 is a trispecific antibody that targets DLL3 on tumor cells and competitively binds to CD3 and TNFRSF9 (CD137), which results in increased CD3 and TNFRSF9 (CD137) signaling and activation of T-cells, potentially leading to decreased growth of DLL3-positive tumors (PMID: 38558120). |
| DrugClasses | CD3 Antibody 119 |
| CAS Registry Number | NA |
| NCIT ID | C198701 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + RO7616789 | Carboplatin RO7616789 | 0 | 0 |
| Cisplatin + RO7616789 | Cisplatin RO7616789 | 0 | 0 |
| RO7616789 | RO7616789 | 0 | 1 |
| RO7616789 + Tocilizumab | RO7616789 Tocilizumab | 0 | 0 |